Efficacy and safety of the RAF dimer selective inhibitor naporafenib, in combination with trametinib or with the ERK inhibitor LTT462, is being explored in another phase I clinical trial (NCT02974725) in advanced or metastatic KRAS- or BRAF-mutant NSCLC progressed following standard therapy. Here, KRAS is linked to non-small cell lung carcinoma.